tbuckley/cabot-search huggingface dataset:
Tumor cell E-selectin ligands determine partialefficacy of bortezomib on spontaneous lung metastasis formation of solid human tumors in vivo
Authors: Tobias Lange, Ursula Valentiner, Daniel Wicklein, Hanna Maar, Vera Labitzky, Ann-Kristin Ahlers, Sarah Starzonek, Sandra Genduso, Lisa Staffeldt, Carolin Pahlow, Anna-Maria Dück, Christine Stürken, Anke Baranowsky, Alexander T. Bauer, Etmar Bulk, Albrecht Schwab, Kristoffer Riecken, Christian Börnchen, Rainer Kiefmann, Valsamma Abraham, Horace M. DeLisser, Timo Gemoll, Jens K. Habermann, Andreas Block, Klaus Pantel, Udo Schumacher
Journal: Molecular Therapy (2022)

Extravasation of circulating tumor cells (CTCs) is critical for metastasis and is initiated by adhesive interactions between glycoligands on CTCs and E-selectin on endothelia. Here, we show that the clinically approved proteasome inhibitor bortezomib (BZM; Velcade) counteracts the cytokine-dependent induction of E-selectin in the lung mediated by the primary tumor, thereby impairing endothelial adhesion and thus spontaneous lung metastasis in vivo. However, the efficacy of BZM crucially depends on the tumor cells' E-selectin ligands, which determine distinct adhesion patterns. The canonical ligands sialyl-Lewis A (sLeA) and sLeX mediate particularly high-affinity E-selectin binding so that the incomplete E-selectin-reducing effect of BZM is not sufficient to disrupt adhesion or metastasis. In contrast, tumor cells lacking sLeA/X nevertheless bind E-selectin, but with low affinity, so that adhesion and lung metastasis are significantly diminished. Such low-affinity E-selectin ligands apparently consist of sialylated MGAT5 products on CD44. BZM no longer has anti-metastatic activity after CD44 knockdown in sLeA/X-negative tumor cells or E-selectin knockout in mice. sLeA/X can be determined by immunohistochemistry in cancer samples, which might aid patient stratification. These data suggest that BZM might act as a drug for inhibiting extravasation and thus distant metastasis formation in malignancies expressing low-affinity E-selectin ligands.
Highlights From the <i>Circulation</i> Family of Journals
Journal: Circulation (2021)

This month's highlights from the subspecialty journals cover atrial fibrillation, microvascular dysfunction, progression of atherosclerosis, a stroke quality initiative, and a subanalysis of DAPAHF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure). Applying an artificial intelligence algorithm to sinus rhythm ECGs independently predicts atrial fibrillation in a study from Circulation: Arrhythmia and Electrophysiology. In Circulation: Genomic and Precision Medicine, the association of alcohol intake with atrial fibrillation was evaluated according to genetic predisposition to atrial fibrillation. In Circulation: Cardiovascular Interventions, a randomized trial of ranolazine treatment for microvascular dysfunction is reported. In Circulation: Cardiovascular Imaging, baseline 18F-sodium florid activity by positron emission tomography was associated with incident coronary calcification. The Target: Stroke quality initiative from the American Heart Association is reported in Circulation: Cardiovascular Quality and Outcomes. A substudy in Circulation: Heart Failure evaluates the benefit of dapagliflozin across cohorts of duration of heart failure from DAPA-HF.
Predictors of door-to-balloon delay in primary angioplasty Brad G. Angeja, Richard Chin, Priscilla Hsue, Paul D. Frederick, Nathan R. Every, Allen M. Ross, Hal V. Barron, C. Michael Gibson, National Registry of Myocardial Infarction 2?3. University of California, San Francisco, Cardiovascular Research Center, George Washington University, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update
Authors: Michael J. Mauro, Shaker Dakhil, Jorge E. Cortes, David A. Rizzieri, Christopher H Keir, Sandy Yi, Michael C. Heinrich, Stuart L. Goldberg, Rosalind Catchatourian, Philip Kuriakose, Jerald P Radich
Journal: Blood (2014)
Infectious disease surveillance update
Authors: Nicolas Dolan
Journal: The Lancet Infectious Diseases (2014)

As of May 5, 127 confirmed cases of Ebola, including 83 deaths, have been reported by the Ministry of Health of Guinea since the outbreak began in mid-March. Two patients remain in isolation: one in Guekedou and one in Conakry as of May 2. In Liberia, which has six confirmed cases, active surveillance continues but there have been no new clinical cases since April 6. No cases of Ebola have been confirmed in Sierra Leone as of May 7. Guinea and Liberia have deployed prevention and control activities including awareness and education programmes.
Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
Authors: René-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, Julien Lazarovici, Hervé Ghesquieres, Aspasia Stamatoullas, Jehan Dupuis, Anne-Claire Gac, Thomas Gastinne, Bertrand Joly, Krimo Bouabdallah, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Franck Morschhauser, David Sibon, Christophe Bonnet, Alina Berriolo-Riedinger, Véronique Edeline, Marie Parrens, Diane Damotte, Diane Coso, Marc André, Michel Meignan, Cédric Rossi
Journal: Journal of Clinical Oncology (2022)

The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission tomography (PET)-driven de-escalation strategy after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) provides similar progression-free survival (PFS) and overall survival (OS) and reduces early toxicity compared with a nonmonitored standard treatment. Here, we report, with a prolonged follow-up, the final study results.Patients with advanced Hodgkin lymphoma (stage III, IV, or IIB with mediastinum/thorax ratio > 0.33 or extranodal involvement) age 16-60 years were prospectively randomly assigned between 6 × BEACOPP and a PET-driven arm after 2 × BEACOPP delivering 4 × ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in PET2- and 4 × BEACOPP in PET2+ patients. PET performed after four cycles of chemotherapy had to be negative to complete the planned treatment.In total, 823 patients were enrolled including 413 in the standard arm and 410 in the PET-driven arm. With a 67.2-month median follow-up, 5-year PFS (87.5% v 86.7%; hazard ratio [HR] = 1.07; 95% CI, 0.74 to 1.57; P = .67) and OS (97.7% in both arms; HR = 1.012; 95% CI, 0.50 to 2.10; P = .53) were similar in both randomization arms. In the whole cohort, full interim PET assessment predicted patients' 5-year PFS (92.3% in PET2-/PET4-, 75.4% [HR = 3.26; 95% CI, 18.3 to 5.77] in PET2+/PET4- and 46.5% [HR = 12.4; 95% CI, 7.31 to 19.51] in PET4+ patients, respectively; P < .0001) independent of international prognosis score. Five-year OS was also affected by interim PET results, and PET2+/PET4- patients (93.5%; HR = 3.3; 95% CI, 1.07 to 10.1; P = .036) and PET4+ patients (91.9%; HR = 3.756; 95% CI, 1.07 to 13.18; P = .038) had a significant lower OS than PET2-/PET4- patients (98.2%). Twenty-two patients (2.7%) developed a second primary malignancy, 13 (3.2%) and 9 (2.2%) in the standard and experimental arms, respectively.The extended follow-up confirms the continued efficacy and favorable safety of AHL2011 PET-driven strategy, which is noninferior to standard six cycles of BEACOPP. PET4 provides additional prognostic information to PET2 and allows identifying patients with particularly poor prognosis.
SURGERY.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hormone replacement therapy predicts outcome in women with advanced heart failure JoAnn Lindenfeld, Jalal K. Ghali, Heidi J. Krause-Steinrauf, Surai Thaneemit-Chen, Rhonda L. Larsen, Brian D. Lowes, Yves D. Rosenberg, For BEST Investigators. University of Colorado Health Sciences Center, Denver, CO
Journal: Journal of the American College of Cardiology (2001)
A Novel CXCR4 Antagonist IgG1 Antibody (PF-06747143) for the Treatment of Hematological Malignancies
Authors: Flavia Pernasetti, Shu-Hui Liu, Max Hallin, Yin Gu, Wei-Hsien Ho, Cathy Zhang, Bernadette Pascual, Brett Simmons, Zhengming Yan, Nanni Huser, Wenlian Wang, Justine Lam, Mary E Spilker, Eileen Blasi, Thomas-Toan Tran, Jyothirmayee Kudaravalli, Jing-Tyan Ma, Sherman Michael Chin, David Shelton, Tod Smeal, Valeria Fantin
Journal: Blood (2014)
COVID-19 in the USA: a question of time
Authors: None The Lancet
Journal: The Lancet (2020)

With more than 600 000 confirmed cases and close to 27 000 deaths, the USA has become the current centre of the global coronavirus disease 2019 (COVID-19) pandemic. Fewer than 3 months have elapsed since the first severe acute respiratory syndrome coronavirus 2 infection in Washington State was confirmed by the US Centers for Disease Control and Prevention (CDC). Initially appearing slow moving and constrained in contrast to the scale of outbreaks in China and Italy, COVID-19 has given way to a nationwide public health catastrophe.
Tackling the Digital Divide
Authors: None The Lancet Healthy Longevity
Journal: The Lancet Healthy Longevity (2021)

This year, Oct 1 marks International Day for Older Persons 2021, Oct 14, the Chinese Double Ninth Festival—an ancient festival which has included celebration of older adults since 1989—and Oct 21, the one-year anniversary of The Lancet Healthy Longevity's launch. It would seem an auspicious time to reflect. In the past year, the COVID-19 pandemic continues to cause drive excess mortality worldwide, even as vaccines are rolled out with varying degrees of access and success around the world. One of the most striking characteristics of the pandemic is the disproportionately worse outcomes experienced by older people.
Selected Abstracts
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Red-light-triggered self-destructive mesoporous silica nanoparticles for cascade-amplifying chemo-photodynamic therapy favoring antitumor immune responses
Authors: Yanjun Yang, Fangman Chen, Ning Xu, Qichao Yao, Ran Wang, Xiaochun Xie, Fan Zhang, Yan He, Dan Shao, Wen-fei Dong, Jiangli Fan, Wen Sun, Xiaojun Peng
Journal: Biomaterials (2022)
Use of Germline <i>BRCA</i> Testing in Patients With Ovarian Cancer and Commercial Insurance
Authors: Stephanie Cham, Mary Beth Landrum, Nancy L. Keating, Joanne Armstrong, Alexi A. Wright
Journal: JAMA Network Open (2022)

Among 3603 women with ovarian cancer (mean [SD] age, 57.0 [11.3] years), 1220 (33.9%) received gBRCA testing (Table ).Testing rates increased from 14.7% (55 of 375 patients) in 2008 to 46.4% (96 of 207 patients) in 2018; the median time to testing decreased from 280.0 to 72.5 days (Figure).In adjusted analyses, testing was lower for older women (women Ն65 years vs <50 years: adjusted difference, -20.8 percentage points; 95% CI, -25.8 to -16.4 percentage points) and women with more comorbidities (Charlson Comorbidity Index score Ն2 vs 0: adjusted difference, -4.6 percentage points; 95% CI, -8.9 to -0.2 percentage points).Testing rates were similar among oncologists (medical vs gynecologic oncologist: adjusted difference, 1.5 percentage points; 95% CI,
A Noncontrast CMR Risk Score for Long-Term Risk Stratification in Reperfused ST-Segment Elevation Myocardial Infarction
Authors: Heerajnarain Bulluck, Jaclyn Carberry, David Carrick, Peter J. McCartney, Annette M. Maznyczka, John P. Greenwood, Neil Maredia, Saqib Chowdhary, Anthony H. Gershlick, Clare Appleby, James M. Cotton, Andrew Wragg, Nick Curzen, Margaret McEntegart, Mark C. Petrie, Hany Eteiba, Stuart Watkins, Mitchell Lindsay, Ahmed Mahrous, Keith G. Oldroyd, Colin Berry
Journal: JACC. Cardiovascular imaging (2022)
Effects of atorvastatin treatment on global fibrinolytic capacity, apoptosis, and leukocyte activation in patients with coronary artery disease Enver Atalar, Tayfun Ac�l, Kudret Aytemir, �brahim Haznearoglu, Necla �zer, Altunay Daver, Kenan �v�n�, Serdar Aks�yek, S�rr� Kes, Ferhan �zmen. Hacetteppe University Medical School Departments of Cardiology and Hematology, Ankara, Turkey
Journal: Journal of the American College of Cardiology (2001)
Tardive Dyskinesia
Authors: D Tarsy, R J Baldessarini
Journal: Annual Review of Medicine (1984)

CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 ...Read More
'Uncle George' resurrected
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis
Authors: Linjun Shi, Yuquan Yang, Mengying Li, Chenxi Li, Zengtong Zhou, Guoyao Tang, Lan Wu, Yilin Yao, Xuemin Shen, Zhaoyuan Hou, Hao Jia
Journal: Molecular Therapy (2022)

Oral squamous cell carcinoma (OSCC), which is typically preceded by oral leukoplakia (OL), is a common malignancy with poor prognosis. However, the signaling molecules governing this progression remain to be defined. Based on microarray analysis of genes expressed in OL and OSCC samples, we discovered that the long non-coding RNA IFITM4P was highly expressed in OSCC, and ectopic expression or knockdown of IFITM4P resulted in increased or decreased cell proliferation in vitro and in xenografted tumors, respectively. Mechanistically, in the cytoplasm IFITM4P acted as a scaffold to facilitate recruiting SASH1 to bind and phosphorylate TAK1 (Thr187), and in turn to increase the phosphorylation of nuclear factor κB (Ser536) and concomitant induction of PD-L1 expression, resulting in activation of an immunosuppressive program that allows OL cells to escape anti-cancer immunity in cytoplasm. In nucleus, IFITM4P reduced Pten transcription by enhancing the binding of KDM5A to the Pten promoter, thereby upregulating PD-L1 in OL cells. Moreover, mice bearing tumors with high IFITM4P expression had notable therapeutic sensitivity to PD-1 monoclonal antibody (mAb) treatment. Collectively, these data demonstrate that IFITM4P may serve as a new therapeutic target in blockage of oral carcinogenesis, and PD-1 mAb can be an effective reagent to treat OSCC.
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
Authors: Samuel J Klempner, Joseph Chao, Hope Elizabeth Uronis, Cynthia A. Sirard, Michael Kagey, Jason Baum, James Song, Jin Wang, In-Ho Kim, Keun Wook Lee, Do-Youn Oh, Bassam Bassam Sonbol, Zev A. Wainberg, Jaffer A. Ajani
Journal: Journal of Clinical Oncology (2022)

292 Background: Despite recent approval of anti-PD-1 antibodies as 1L therapy in HER2(-) advanced GEA, benefit remains modest and limited largely to PD-L1(+) patients (pts), primarily those with combined positive scores (CPS) ≥5. Thus novel therapeutic approaches are needed for this pt population. DKN-01 is a targeted anti-DKK1 mAb which has demonstrated improved clinical outcomes in pts with elevated tumoral DKK1 expression, a subset of pts with more aggressive disease and shorter overall survival. Methods: DisTinGuish (NCT04363801) is a Phase 2a single arm 2-part trial; Part A investigated DKN-01 (D) + tislelizumab (TS) + CAPOX as 1L therapy for pts with advanced HER2(-) GEA regardless of DKK1 status; Part B investigated two dosing cohorts of D (300 mg and 600 mg) + TS as 2L therapy for DKK1-high advanced GEA pts. Primary objective was to examine safety and tolerability and secondary objectives evaluated multiple efficacy endpoints including overall response rate (ORR) in a modified intent to treat (mITT) population (&gt;1 dose D). Results: Forty-nine pts enrolled between 01 Sept 2020 and 15 Sept 2021; 25 pts in Part A and 24 pts in Part B (D-300 mg). Key clinicopathologic features and efficacy outcomes are shown in Table. The most common D-related AEs were low grade (G1/2) fatigue, nausea, and diarrhea. Nine pts had D-related ≥G3 toxicities, elevated AST/ALT, elevated alkaline phosphatase, hypophosphatemia, hyponatremia, lymphopenia, neutropenia, diarrhea, vomiting, fatigue all occurring in 1 pt and pulmonary embolism in 2 pts (one G5 event). No new safety signals were observed in Part A or B1. Duration of response (DoR), median PFS and median OS have not been reached for Part A. Last pt enrolled in Part B1 on 15 Sept 2021. Conclusions: The combination of D/TS + CAPOX represents a well-tolerated, active 1L combination, particularly for DKK1-high patients consistent with the proposed mechanism of action. Activity appears to be independent of PD-L1 status. Part B1 is aligned with biomarker enrichment and efficacy and biomarker data will be presented along with updated Part A efficacy data. Clinical trial information: NCT04363801. [Table: see text]
Corrigendum
Journal: BMJ (1932)

JOURNAL~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~If, on the other hand, the partners do not combine to give such a notice, then the previous year's basis will continue to be applicable, the assessment for the year 1932-3 will remain unaltered, and that for 1933-4 will be determined by the amount of the net earnings for the year to March 31st, 1933.A will not be taxable in respect of his share of debts collected and paid over to him after his retirement.Holiday Duity: Expenises "J.L. T." was superannuated from a wvhole-time appoint- ment, but asked to do holiday duty for the same authority.This necessitated leaving his home and living in rooms or.institutions.Wrhen residing temporarily in an institution a deduction at the rate of '£100 per annum w-as made for board-residence.Can he deduct from the emoluments earned the sums paid, by> deduction or otherwi5e, for the cost of
COVID-19 and haematology-oncology services
Authors: None The Lancet Haematology
Journal: The Lancet Haematology (2020)

As the COVID-19 pandemic continues to develop, the situation for patients with haematological malignancies is also evolving. With the effects on health-care systems still being felt, and the enormous global research effort to uncover the biological mechanisms of COVID-19, an expert consensus for how to treat patients with cancer during the pandemic was published last month by the European Society of Medical Oncology. Key recommendations include the need to test patients regularly for the virus, and to proceed with treatments as much as possible, taking the local infection rate into consideration.
MEDICAL RESEARCH SUPPORTED BY TAX ON FIREWORKS.
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EFFECT OF BODY MASS INDEX ON THE BENEFIT OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN PATIENTS WITH HEART FAILURE
Authors: Firas Zahwe, Amine Segueni, Naoyo Mori, Mohamed Rahman, Andleeb Bangash, Vincent Keating, Alix J. Tercius, Ilhem Remmouche, Marc A. Silver, M. Eyman Mortada
Journal: Journal of the American College of Cardiology (2011)